TLR agonist rHP-NAP as an Adjuvant of Dendritic Cell-Based Vaccine to Enhance Anti-Melanoma Response
Background: Melanoma is a common and malignant cutaneous tumor, which is responsible for a large proportion of skin cancer deaths. Dendritic cell (DC)-based vaccines have achieved positive results in the treatment of melanoma because of their ability to induce cytotoxic response to facilitate tumor...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Shiraz University of Medical Sciences
2020-03-01
|
Series: | Iranian Journal of Immunology |
Subjects: | |
Online Access: | https://iji.sums.ac.ir/article_46472_0702ab433bd224599f8c3fe5028e909c.pdf |
id |
doaj-f4d7030344e24b18965611607d77b7e8 |
---|---|
record_format |
Article |
spelling |
doaj-f4d7030344e24b18965611607d77b7e82021-02-24T11:21:32ZengShiraz University of Medical SciencesIranian Journal of Immunology1735-13831735-367X2020-03-01171142510.22034/iji.2020.8029146472TLR agonist rHP-NAP as an Adjuvant of Dendritic Cell-Based Vaccine to Enhance Anti-Melanoma ResponseMeiling Hou0Xiaodong Wang1Jike Lu2Xun Guo3Cong Ding4Taotao Liang5Zhenyu Ji6Peng Xie7Xin Liu8Qiaozhen Kang9School of Life Sciences, Zhengzhou University, Zhengzhou, PR ChinaSchool of Life Sciences, Zhengzhou University, Zhengzhou, PR ChinaSchool of Life Sciences, Zhengzhou University, Zhengzhou, PR ChinaSchool of Life Sciences, Zhengzhou University, Zhengzhou, PR ChinaSchool of Life Sciences, Zhengzhou University, Zhengzhou, PR ChinaSchool of Life Sciences, Zhengzhou University, Zhengzhou, PR ChinaHenan Academy of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, PR ChinaZhengzhou Xinzhiyi Biotechnology Co., Zhengzhou, PR ChinaSchool of Life Sciences, Zhengzhou University, Zhengzhou, PR ChinaSchool of Life Sciences, Zhengzhou University, Zhengzhou, PR ChinaBackground: Melanoma is a common and malignant cutaneous tumor, which is responsible for a large proportion of skin cancer deaths. Dendritic cell (DC)-based vaccines have achieved positive results in the treatment of melanoma because of their ability to induce cytotoxic response to facilitate tumor elimination. Objective: To improve the efficacy of dendritic cell-based vaccines by the adjuvant activity of Helicobacter pylori neutrophil activating protein (HP-NAP), which is a virulence factor of Helicobacter pylori, has been proved as a TLR agonist with effective immunomodulatory activity. Methods: The recombinant HP-NAP (rHP-NAP) was expressed by using prokaryotic expression system. Dendritic cells (DCs) were cultured with granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-4. After treating with rHP-NAP, the maturation of DCs and dendritic cell-based vaccine were assayed by using flow cytometry and qRT-PCR. The activation and proliferation of T cells were measured by FCM, ELISA and MTT methods. The tumor specific cytotoxic response to resistant B16F10 was detected by using lactate dehydrogenase-release assay and qRT-PCR. Results: The recombinant HP-NAP (rHP-NAP), prepared from E. coli prokaryotic expression system, was able to significantly promote the maturation of dendritic cell-based vaccine loaded with tumor cell lysate (TCL) of B16F10 (DC-B16F10-TCL). Furthermore, it effectively induced the activation and proliferation of T cells and tumor specific cytotoxic response to resistant B16F10 melanoma tumor cells. Conclusion: These results suggested that rHP-NAP possesses the potential for use as an adjuvant of dendritic cell-based vaccine in anti-melanoma treatment.https://iji.sums.ac.ir/article_46472_0702ab433bd224599f8c3fe5028e909c.pdfcytotoxic responsedendritic cell-based vaccinemelanomarhp-nap |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Meiling Hou Xiaodong Wang Jike Lu Xun Guo Cong Ding Taotao Liang Zhenyu Ji Peng Xie Xin Liu Qiaozhen Kang |
spellingShingle |
Meiling Hou Xiaodong Wang Jike Lu Xun Guo Cong Ding Taotao Liang Zhenyu Ji Peng Xie Xin Liu Qiaozhen Kang TLR agonist rHP-NAP as an Adjuvant of Dendritic Cell-Based Vaccine to Enhance Anti-Melanoma Response Iranian Journal of Immunology cytotoxic response dendritic cell-based vaccine melanoma rhp-nap |
author_facet |
Meiling Hou Xiaodong Wang Jike Lu Xun Guo Cong Ding Taotao Liang Zhenyu Ji Peng Xie Xin Liu Qiaozhen Kang |
author_sort |
Meiling Hou |
title |
TLR agonist rHP-NAP as an Adjuvant of Dendritic Cell-Based Vaccine to Enhance Anti-Melanoma Response |
title_short |
TLR agonist rHP-NAP as an Adjuvant of Dendritic Cell-Based Vaccine to Enhance Anti-Melanoma Response |
title_full |
TLR agonist rHP-NAP as an Adjuvant of Dendritic Cell-Based Vaccine to Enhance Anti-Melanoma Response |
title_fullStr |
TLR agonist rHP-NAP as an Adjuvant of Dendritic Cell-Based Vaccine to Enhance Anti-Melanoma Response |
title_full_unstemmed |
TLR agonist rHP-NAP as an Adjuvant of Dendritic Cell-Based Vaccine to Enhance Anti-Melanoma Response |
title_sort |
tlr agonist rhp-nap as an adjuvant of dendritic cell-based vaccine to enhance anti-melanoma response |
publisher |
Shiraz University of Medical Sciences |
series |
Iranian Journal of Immunology |
issn |
1735-1383 1735-367X |
publishDate |
2020-03-01 |
description |
Background: Melanoma is a common and malignant cutaneous tumor, which is responsible for a large proportion of skin cancer deaths. Dendritic cell (DC)-based vaccines have achieved positive results in the treatment of melanoma because of their ability to induce cytotoxic response to facilitate tumor elimination. Objective: To improve the efficacy of dendritic cell-based vaccines by the adjuvant activity of Helicobacter pylori neutrophil activating protein (HP-NAP), which is a virulence factor of Helicobacter pylori, has been proved as a TLR agonist with effective immunomodulatory activity. Methods: The recombinant HP-NAP (rHP-NAP) was expressed by using prokaryotic expression system. Dendritic cells (DCs) were cultured with granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-4. After treating with rHP-NAP, the maturation of DCs and dendritic cell-based vaccine were assayed by using flow cytometry and qRT-PCR. The activation and proliferation of T cells were measured by FCM, ELISA and MTT methods. The tumor specific cytotoxic response to resistant B16F10 was detected by using lactate dehydrogenase-release assay and qRT-PCR. Results: The recombinant HP-NAP (rHP-NAP), prepared from E. coli prokaryotic expression system, was able to significantly promote the maturation of dendritic cell-based vaccine loaded with tumor cell lysate (TCL) of B16F10 (DC-B16F10-TCL). Furthermore, it effectively induced the activation and proliferation of T cells and tumor specific cytotoxic response to resistant B16F10 melanoma tumor cells. Conclusion: These results suggested that rHP-NAP possesses the potential for use as an adjuvant of dendritic cell-based vaccine in anti-melanoma treatment. |
topic |
cytotoxic response dendritic cell-based vaccine melanoma rhp-nap |
url |
https://iji.sums.ac.ir/article_46472_0702ab433bd224599f8c3fe5028e909c.pdf |
work_keys_str_mv |
AT meilinghou tlragonistrhpnapasanadjuvantofdendriticcellbasedvaccinetoenhanceantimelanomaresponse AT xiaodongwang tlragonistrhpnapasanadjuvantofdendriticcellbasedvaccinetoenhanceantimelanomaresponse AT jikelu tlragonistrhpnapasanadjuvantofdendriticcellbasedvaccinetoenhanceantimelanomaresponse AT xunguo tlragonistrhpnapasanadjuvantofdendriticcellbasedvaccinetoenhanceantimelanomaresponse AT congding tlragonistrhpnapasanadjuvantofdendriticcellbasedvaccinetoenhanceantimelanomaresponse AT taotaoliang tlragonistrhpnapasanadjuvantofdendriticcellbasedvaccinetoenhanceantimelanomaresponse AT zhenyuji tlragonistrhpnapasanadjuvantofdendriticcellbasedvaccinetoenhanceantimelanomaresponse AT pengxie tlragonistrhpnapasanadjuvantofdendriticcellbasedvaccinetoenhanceantimelanomaresponse AT xinliu tlragonistrhpnapasanadjuvantofdendriticcellbasedvaccinetoenhanceantimelanomaresponse AT qiaozhenkang tlragonistrhpnapasanadjuvantofdendriticcellbasedvaccinetoenhanceantimelanomaresponse |
_version_ |
1724253038963589120 |